Survodutide suppresses appetite and boosts liver fat burning simultaneously, the first GLP-1/glucagon dual agonist to file an NDA. Phase 2 showed 19% weight loss plus 62.9% liver disease resolution. FDA decision expected late 2026 or 2027.
Survodutide achieved up to 19% weight loss in Phase 2, plus 62.9% liver disease resolution. The NDA was filed February 2026. FDA decision expected in late 2026 or early 2027.
A weekly injection that tackles weight from two angles: less appetite in, more liver fat burned out. It's the next generation beyond GLP-1 drugs, targeting a second receptor that fires up fat burning in the liver.
GLP-1 drugs like Wegovy and Zepbound reduce how much you eat by signaling fullness in the brain. Survodutide does that too, but it adds a second attack: activating the glucagon receptor in the liver.
Glucagon activation directly increases liver metabolism and fat burning. While GLP-1 reduces calories coming in, glucagon increases calories being burned, particularly visceral (liver) fat. This dual approach is why Survodutide showed not just strong weight loss (19%) but also 62.9% NASH resolution in people with liver disease, something no GLP-1 drug alone has achieved.
Boehringer Ingelheim filed the NDA in February 2026, making Survodutide one of the weight loss drugs closest to potential FDA approval.
GLP-1 cuts appetite. Glucagon boosts liver fat burning. Together they produce stronger results than either alone. Each receptor does something different and complementary. Together, they attack weight from two separate angles simultaneously.
One subcutaneous injection per week, self-administered. Dose is escalated gradually over the first months to reduce GI side effects and improve tolerance.
Both GLP-1 and glucagon receptors activate simultaneously, suppressing appetite in the brain while ramping up liver metabolism at the same time.
You eat less because of appetite suppression, while your liver burns fat faster from glucagon activation. The dual effect explains why results exceed GLP-1 drugs alone.
Phase 2 obesity trial: 19% at 46 weeks. SYNCHRONIZE-NAFLD Phase 3: 15.7% weight loss + 62.9% NASH resolution. Survodutide has two major data sets: the Phase 2 obesity trial showing weight loss efficacy, and the SYNCHRONIZE-NAFLD Phase 3 trial showing combined weight and liver benefit published in The Lancet (January 2026).
NASH (non-alcoholic steatohepatitis) affects tens of millions of Americans and has very few treatment options. Survodutide's ability to achieve 62.9% NASH resolution at 48 weeks, published in The Lancet in January 2026, is a landmark result. No approved GLP-1 drug has demonstrated this level of liver benefit. This makes Survodutide particularly important for the large overlap of patients with obesity and liver disease.
NDA filed February 2026. FDA decision expected late 2026-early 2027. Survodutide is one of the most advanced weight loss drugs in the pipeline, the NDA is already filed and Phase 3 trials are completing.
With the NDA already filed, Survodutide could be the first of this new wave of obesity drugs to reach patients, possibly as early as late 2026 or early 2027.
Search Open Trials →"Glucagon gets a bad reputation in weight loss conversations because of what it does to blood sugar. What's interesting about survodutide is how the GLP-1 component seems to offset that. The liver effects are what I find most clinically interesting here."
Endocrine Surgeon · GLP-1 Specialist
Not available yet, but FDA decision possible in 2026. Especially strong fit for people with obesity and liver disease. Survodutide's dual mechanism, weight loss plus liver benefit, makes it uniquely suited for a specific patient profile.
⚕️ Always consult your doctor before starting or changing any weight loss treatment.
Survodutide vs approved drugs and other pipeline medications. Stacking Survodutide against what's currently available and what's coming in the pipeline.
| Drug | Weight Loss | Mechanism | Form | Status |
|---|---|---|---|---|
| 💉Survodutide You're here | 19% (Ph2) | GLP-1 + Glucagon | Weekly injection | NDA Filed |
| 💉Retatrutide | 24% (Ph2) | Triple Agonist (GLP-1/GIP/Glucagon) | Weekly injection | Phase 3 |
| 💉CagriSema | 22.7% (Ph3) | GLP-1 + Amylin | Weekly injection | NDA Filed |
| 💉Zepbound | 21% | Dual Agonist (GLP-1, GIP) | Weekly injection | ✓ Approved |
| 💉Wegovy | 15% | GLP-1 Agonist | Weekly injection | ✓ Approved |
Phase 2 numbers are from clinical trials, not direct drug-to-drug comparisons. Interpret any cross-trial numbers carefully.